abstract |
Disclosed herein are bispecific T cell receptor mimetic (TCRm) mAbs that are reactive against human immune effector cell antigens and WT1 peptide / HLA-A epitopes. This antibody selectively binds to leukemia and solid tumor cells expressing WT1 and HLA-A, and activated quiescent human T cells, releasing interferon (IFN-γ) and inducing target cancer cells in vitro. I was killed. Importantly, this antibody mediated autologous T cell proliferation and directed potent cytotoxic activity against fresh ovarian cancer cells. The in vivo therapeutic activity of this antibody is NOD with three different human cancers expressing WT1 / HLA-A2, including disseminated Ph + acute lymphoblastic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. It was demonstrated in SCID SCID γc * (NSG) mice. |